Clinical course of metastatic parathyroid cancer. World J Surg 1994 Jul-Aug;18:594-598.
Molecular diagnosis of primary hyperparathyroidism in familial cancer syndromes. Expert Opin Med Diagn 2007 Nov;1(3):377-392.
Accuracy of combined protein gene product 9.5 and parafibromin markers for immunohistochemical diagnosis of parathyroid carcinoma. J Clin Endocrinol Metab 2009 Feb;94(2):434-441.
Endocr Relat Cancer 2012 May 24;19(3):389-407.
Large parathyroid tumors have an increased risk of atypia and carcinoma. Am J Surg 2011 Aug;202(2):146-150.
Loss of parafibromin immunoreactivity is a distinguishing feature of parathyroid carcinoma. Clin Cancer Res 2004 Oct 1;10(19):6629-6637.
Loss of nuclear expression of parafibromin distinguishes parathyroid carcinomas and hyperparathyroidism-jaw tumor (HPT-JT) syndrome-related adenomas from sporadic parathyroid adenomas and hyperplasias. Am J Surg Pathol 2006;30:1140-1149.
Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma. N Engl J Med 2003 Oct;349(18):1722-1729.
HRPT2 mutations are associated with malignancy in sporadic parathyroid tumors. J Med Genet 2003 Sep;40(9):657-663.
The parafibromin tumor suppressor protein inhibits cell proliferation by repression of the cmyc proto-oncogene. Proc Natl Acad Sci USA 2008 Nov 11;105(45):17420-17425.
Parathyroid carcinoma. A study of 70 cases. Cancer 1973 Mar;31(3):600-605.
Parafibromin immunoreactivity: its use as an additional diagnostic marker for parathyroid tumor classification. Endocr Relat Cancer 2007 Jun;14(2):501-512.
